Skip to content

Development and Validation of Predictive Model for Autoimmune Encephalitis Clinical Diagnosis

Development and Validation of Predictive Model for Autoimmune Encephalitis Clinical Diagnosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600129290
Enrollment
Unknown
Registered
2026-08-03
Start date
2026-08-07
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune encephalitis (AIE)

Interventions

cohort of patients with suspected AIE:NA
cohort of patients with confirmed AIE:NA

Sponsors

Punan Hospital, Pudong New Area, Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years, both genders. 2. Attending the neurology department of one of the three collaborating hospitals and meeting the diagnostic criteria for suspected or confirmed autoimmune encephalitis (AIE). 3. Patients with confirmed AIE must have completed routine imaging examinations and immunological tests, with complete data, and be able to cooperate with short-term efficacy evaluation and long-term follow-up. 4. Voluntarily participate in this study and sign the informed consent form. 5. For patients in the retrospective cohort, informed consent is supplemented by their family members or legally authorized representatives (if applicable).

Exclusion criteria

Exclusion criteria: 1. Subjects unwilling to participate in the clinical study. 2. Combined severe dysfunction of vital organs such as the heart, liver, kidneys, or lungs, making it impossible to complete the relevant examinations and follow-up. 3. Combined with other autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, etc.) that may affect the study results. 4. Pregnant or breastfeeding women. 5. Patients with psychiatric disorders who are unable to cooperate with data collection and assessment. 6. Incomplete data that cannot be included in the statistical analysis. 7. Patients who have not completed the main diagnosis, treatment, and examination processes at the above-mentioned three collaborating hospitals, and thus cannot provide complete study data.

Design outcomes

Primary

MeasureTime frame
The core predictive indicators and cutoff values of the sample submission decision-making model;

Secondary

MeasureTime frame
Modified Rankin Scale;Collect the treatment plans, treatment responses and follow-up data of patients diagnosed with AIE, and record the NEOS score and NEOS2 score;radiologic characteristic;Immunology data;

Countries

China

Contacts

Public ContactWang Kan, Guan Yangtai

Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine

21221@renji.com+86 21 20302000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026